Translating Pembrolizumab to Clinical Practice: Speak Immunology and Learn Fast!
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 26169966.
- Also identified by DOI 10.1158/1078-0432.CCR-15-1126.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
T-cell checkpoint inhibitors treat the cancer patient's immune system potentially inducing significant long-term survival. Pembrolizumab demonstrates clinical activity in patients diagnosed with melanoma and other cancers. Its mode of action suggests a rationale for combination with other treatment modalities, urging oncologists to brush up their knowledge of immunology.
Medical subject headings
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents
- Neoplasms